Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy
Status:
Not yet recruiting
Trial end date:
2026-03-14
Target enrollment:
Participant gender:
Summary
Gestational trophoblastic Neoplasia（GTN） is a kind of malignant tumor in women of
childbearing age. It is easy to metastasized through the blood system in the early stage, so
it is a relatively malignant tumor. The tumor is highly sensitive to chemotherapy, and
low-risk patients have good prognosis, with survival rate and cure rate approaching 100%, but
high-risk patients are prone to drug resistance, or relapse after remission. For relapsed,
refractory, high-risk GTN, multiple remedies have been reported in the literature, but the
remission rate is only 75-80%. For relapsed or refractory high-risk GTN, multiple remedies
have been reported in the literature, but the remission rate is only 75-80%.
Currently, targeted therapy and immunotherapy are widely used in various refractory solid
tumors. For GTN, there are also a number of related studies. In this study, PD-1 inhibitors
combined with bevacizumab were used to treat refractory high-risk GTN with relapse or drug
resistance after receiving previous second-line or above multidrug combination therapy, to
study the efficacy and safety of the treatment regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Women's Hospital School Of Medicine Zhejiang University